Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07089875 · ClinicalTrials.gov registry record · Phase 3
A Study of Dotinurad Versus Allopurinol in Participants With Gout
A Phase 3 study of Gout, sponsored by Crystalys Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT07089875 is a Phase 3 study of Gout that is actively recruiting participants, run by Crystalys Therapeutics. The registered enrollment target is 500 participants, below the 8,874-participant average among 34 other Gout trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT07089875, a Phase 3 study of Gout, is actively recruiting participants, sponsored by Crystalys Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.
Conditions Studied
Interventions
- DRUG Allopurinol
- DRUG Dotinurad
Study Locations (20)
California
- Medvin Clinical Research - Covina - Covina
- West Coast Research - Dublin
- Infinity Clinical Research - Norco
- Amicis Research Center - Balboa - Northridge
- Dream Team Clinical Research - Pomona
- Velocity Clinical Research - San Bernardino - San Bernardino
- Acclaim Clinical Research, Inc. - San Diego
- East Bay Rheumatology Medical Group - San Leandro
- BTC Network - Encompass Clinical Research - Spring Valley
- Cohen Medical Centers - Thousand Oaks
- Medvin Clinical Research - Tujunga - Tujunga
Arizona
- Arizona Arthritis & Rheumatology Associates (AARA) - Gilbert - Gilbert
- Arizona Arthritis & Rheumatology Associates (AARA) - Glendale - Glendale
- Arizona Arthritis & Rheumatology Associates (AARA) - Mesa - Mesa
- Del Sol Research Management - Tucson East - Tucson
- Del Sol Research Management - Tucson - Tucson
Alabama
- University of Alabama at Birmingham - Birmingham
- Alabama Clinical Therapeutics - Birmingham
Colorado
- Denver Arthritis Clinic - Lowry - Denver
Florida
- Bradenton Research Center - Bradenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2027-11-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07089875
The ClinicalTrials.gov registry entry for NCT07089875 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 8,874-participant average among 34 other Gout trials with a reported enrollment target (94% lower). The listed sponsor is Crystalys Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 2 interventions - of which Allopurinol is the first listed.
NCT07089875 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT07089875 about?
NCT07089875 is a clinical study titled "A Study of Dotinurad Versus Allopurinol in Participants With Gout". The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.
What is the current status of trial NCT07089875?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2025-08-01. Estimated completion is 2027-11-29.
What conditions does trial NCT07089875 study?
This clinical trial studies the following conditions: Gout.
What interventions are being tested in trial NCT07089875?
The interventions under investigation include: Allopurinol (DRUG), Dotinurad (DRUG).
Who is sponsoring clinical trial NCT07089875?
This trial is sponsored by Crystalys Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07089875 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
ACTIVE NOT RECRUITING · Phase 3
-
Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
COMPLETED · Phase 3
-
Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
COMPLETED · Phase 3
-
Combining Lesinurad With Allopurinol in Inadequate Responders
COMPLETED · Phase 3
-
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.